Your browser doesn't support javascript.
loading
Correction: IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma.
Qiao, Y; Zhang, C; Li, A; Wang, D; Luo, Z; Ping, Y; Zhou, B; Liu, S; Li, H; Yue, D; Zhang, Z; Chen, X; Shen, Z; Lian, J; Li, Y; Wang, S; Li, F; Huang, L; Wang, L; Zhang, B; Yu, J; Qin, Z; Zhang, Y.
Affiliation
  • Qiao Y; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Zhang C; Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Li A; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Wang D; Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Luo Z; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Ping Y; Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Zhou B; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Liu S; Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Li H; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Yue D; Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Zhang Z; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Chen X; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Shen Z; School of Life Sciences, Zhengzhou University, Zhengzhou, China.
  • Lian J; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Li Y; School of Life Sciences, Zhengzhou University, Zhengzhou, China.
  • Wang S; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Li F; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Huang L; Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Wang L; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Zhang B; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Yu J; Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Qin Z; Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Zhang Y; Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Oncogene ; 42(44): 3287-3288, 2023 Oct.
Article in En | MEDLINE | ID: mdl-37723312
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Risk_factors_studies Language: En Journal: Oncogene Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2023 Document type: Article Affiliation country: China Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Risk_factors_studies Language: En Journal: Oncogene Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2023 Document type: Article Affiliation country: China Country of publication: Reino Unido